ArticleEndocrine oncology (Bristol, England)2025
Using routinely collected patient data to study the impact of type 2 diabetes on breast cancer.
Article in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Type 2 diabetes mellitus (T2DM) and cancer are prevalent conditions, with evidence linking T2DM to higher breast cancer incidence and mortality. However, it is uncertain whether excess mortality in breast cancer patients with diabetes is driven by cancer-related factors. This study aims to investigate overall survival (OS) and chemotherapy receipt post-surgery in women with diabetes and localised breast cancer. Methods: Cohorts were constructed from electronic patient records on TriNetX, a de-identified patient database. Three cohorts included women with diabetes stratified by localised breast cancer stage (1 & 2, 3 and all), compared to control groups without diabetes. Cohorts were propensity score matched for age, ethnicity, smoking status and BMI. OS and chemotherapy receipt were compared. Results: Patients with diabetes ( Conclusion: We observed significantly poorer OS in women with breast cancer and diabetes across all stages, compared to those without diabetes. Importantly, this persisted after adjusting for confounders and cardiovascular diseases, supporting that diabetes directly influences cancer outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.